Boundless Bio, Inc.

NasdaqGS:BOLD Stock Report

Market Cap: US$33.4m

Boundless Bio Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Zach Hornby

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage39.80%
CEO tenure7yrs
CEO ownership1.1%
Management average tenure3.5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Analysis Article • Feb 04

Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 17

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 13

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 27

Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Compensation Analysis

How has Zach Hornby's remuneration changed compared to Boundless Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$56m

Dec 31 2025US$2mUS$638k

-US$58m

Sep 30 2025n/an/a

-US$62m

Jun 30 2025n/an/a

-US$64m

Mar 31 2025n/an/a

-US$66m

Dec 31 2024US$6mUS$595k

-US$65m

Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$53m

Dec 31 2023US$2mUS$495k

-US$49m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$47m

Dec 31 2022US$693kUS$476k

-US$46m

Compensation vs Market: Zach's total compensation ($USD1.60M) is above average for companies of similar size in the US market ($USD647.55K).

Compensation vs Earnings: Zach's compensation has been consistent with company performance over the past year.

CEO

Zach Hornby (46 yo)

7yrs
Tenure
US$1,603,205
Compensation

Mr. Zachary Hornby, also known as Zach, serves as Director at Radionetics Oncology, Inc. since October 2021. He serves as Director at Novome Biotechnologies, Inc. since May 2021. He was a member of the Boa...

Leadership Team

NamePositionTenureCompensationOwnership
Zachary Hornby
CEO, President & Director7yrsUS$1.60m1.14%
$ 382.1k
Christian Hassig
Chief Scientific Officer6.5yrsUS$875.35k0.11%
$ 38.2k
Robert Doebele
Chief Medical Officer1.3yrsUS$1.02m0%
$ 0
David Hinkle
Senior VP of Finance4.9yrsno datano data
Jessica Oien
Chief Legal Officer & Corporate Secretary4.8yrsno datano data
Meredith Wesley
Chief Human Resources Officerless than a yearno datano data
Amy Berkley
Senior Vice President of Program Team2.3yrsno datano data
James Freddo
Interim Chief Medical Officer1.3yrsno datano data
3.5yrs
Average Tenure
54yo
Average Age

Experienced Management: BOLD's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zachary Hornby
CEO, President & Director7yrsUS$1.60m1.14%
$ 382.1k
George Demetri
Member of Clinical Advisory Board2.6yrsno datano data
Stephen Benkovic
Scientific & Clinical Advisorno datano datano data
Jonathan Lim
Co-Founder & Independent Chairman7.4yrsUS$107.08k0.46%
$ 152.8k
Kristina Burow
Independent Director6.9yrsUS$62.05k0%
$ 0
Benjamin Cravatt
Scientific & Clinical Advisorno dataUS$92.28kno data
Jennifer Lew
Independent Director4.3yrsUS$73.05k0%
$ 0
Paul Mischel
Chairman of Scientific Advisory Boardno datano datano data
James Christensen
Independent Director2.6yrsUS$58.05k0%
$ 0
Nancy Whiting
Independent Director2.6yrsUS$57.05k0%
$ 0
Vineet Bafna
Scientific & Clinical Advisorno datano datano data
4.3yrs
Average Tenure
52.5yo
Average Age

Experienced Board: BOLD's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 16:26
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Boundless Bio, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hiroshi ShibutaniGoldman Sachs
Richard J. LawGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC